Title : Xyloglucan decorated and chitosan functionalized graphene oxide mediated novel anticancer drug delivery approach
The present study focuses on the development of a novel xyloglucan(XG) –decorated and chitosan functionalized graphene oxide mediated drug delivery system for the delivery of Ulvan isolated from green algae Ulvan lactua(UL) as an anticancer model drug. Chitosan-functionalized graphene oxide (GO -CS) were successfully synthesized. The functionalized nanobiocomposite were further decorated with xyloglucan. The nanobiocomposite thus synthesized was loaded with sulphated polysaccharides such as the so called Ulvan (Ulva lactua) from green algae used as anti cancer model drug and characterized by UV-vis Spectroscopy(UV), fourier transform infrared spectroscopy (FTIR), scanning electron microscopy(SEM), transmission Electron Microscopy (TEM), atomic force microscopy (AFM), x-ray diffractometer (XRD) , thermogravimetric analysis(TGA), raman Spectroscopy, x-ray photoelectron spectroscopy (XPS), particle size analyser and zeta potential. The loading and release of ulvan indicated strong pH dependence and imply a bonding interaction between chitosan functionalized graphene oxide and Ulvan. The biocompatibility of the nanobiocomposites was studied via hemolysis and anti-inflammatory and cellular toxicity was assayed by 3(4,5 Dimethylthiazol 2 yl) 2,5 Diphenyltetrazolium bromide (MTT) against U 937 and U87 cell lines.
Audience take away:
• The exploration of seaweed polysaccharides for drug delivery applications is still in its infancy so an attempt has been made to present seaweed polysaccharide as anticancer model drug owing to its properties
• Prepared nanohybrid system offers a novel formulation that combines the unique properties of a biodegradable material, chitosan, graphene oxide and sulphated polysaccharide for biomedical application.
• The introduction of targeting moieties to polysacharrides based nanoparticles will improve their therapeutic efficacy which also reducing side effects and has high potential to address the current challenges in drug delivery.
• Studies on seaweed polysaccharides based nanoparticles both in vitro and in vivo as well as targeted drug release achievable by these systems, which will support their future use in clinical settings.